AI Antibody Deal Ignites US Synthetic DNA Stocks, Soaring 5% Today

TWIST Bioscience Corporation (NASDAQ: TWST) closed at $80.16 on June 15, up 5.24% for the day. Its market capitalization rose by roughly $276 million to about $4.99 billion, with trading volume near 2 million shares.

In its second quarter of fiscal 2026, Twist reported revenue of approximately $111 million, sustaining double-digit year-over-year growth. The company raised its full-year revenue guidance to $442 million–$447 million and projects adjusted EBITDA breakeven in the fourth quarter of fiscal 2026.

Twist has also secured a co-exclusive license to Invenra’s bispecific antibody platform and joined Amazon Web Services’ AI-driven drug discovery program, Amazon Bio Discovery, as a wet-lab partner—expanding its collaborations in both antibody and AI-based drug-development platforms.

Founded in 2013 and headquartered in South San Francisco, Twist Bioscience specializes in synthetic DNA for diagnostics and therapeutic development, industrial and agricultural research, next-generation sequencing libraries, and antibody-discovery solutions. Under founder and CEO Emily Leproust, the company leverages its proprietary DNA synthesis platform and biosecurity research to broaden its footprint in next-generation life-science tools, including AI-assisted protein design.